WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative...
WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical‐stage biopharmaceutical company developing innovative treatments...
WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments...
WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments...
WILMETTE, Ill., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments...
Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Monopar Therapeutics Inc yesterday and set a price target of $109.00. The company’s shares closed yesterday at $98.57.Elevate Your...
In a report released today, Christopher Raymond from Raymond James maintained a Buy rating on Monopar Therapeutics Inc, with a price target of $142.00. The company’s shares closed last Friday at $99.39.Elevate...
Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Monopar Therapeutics Inc today and set a price target of $115.00. The company’s shares closed yesterday at $84.73.Elevate Your Investing...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Maze Therapeutics, Inc. (MAZE – Research Report), Repligen (RGEN – Research Report) and Monopar Therapeutics...
WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics”, “Monopar”, or the “Company”), a clinical-stage biopharmaceutical company...